Delaying Medicare payment changes for oral kidney disease drugs until 2027.
This Act delays the inclusion of oral-only drugs used for managing serum phosphate in End-Stage Renal Disease (ESRD) patients into the Medicare ESRD prospective payment system until January 1, 2027. This extension aims to ensure continued patient access to these essential medications without immediate changes to coverage or costs. Furthermore, the law mandates a study on coverage gaps, drug expenditures, and patient adherence to inform future policy decisions.
Key points
Drug Access: The inclusion of oral phosphate-binding drugs for ESRD patients into the Medicare ESRD payment system is delayed until January 1, 2027, protecting patients from potential cost increases or changes in treatment access.
Study Mandate: A detailed study is required on expenditures for these drugs, patient adherence, and gaps in insurance coverage, which will help develop better treatment strategies and cost reduction methods.
Expired
Citizen Poll